Managing Diabetic Macular Edema in Clinical Practice: Systematic Review and Meta-Analysis of Current Strategies and Treatment Options

References

• Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–564. doi:10.2337/dc11-1909
   PubMed Web of Science ®Google Scholar
• Varma R, Bressler NM, Doan QV, et al. Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol. 2014;132(11):1334–1350. doi:10.1001/jamaophthalmol.2014.2854
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy: IV. Diabetic macular edema. Ophthalmology. 1984;91(12):1464–1474. doi:10.1016/S0161-6420(84)34102-1
   PubMed Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS Report 9. Ophthalmology. 1991;98(Suppl 5):766–785. doi:10.1016/S0161-6420(13)38011-7
   PubMed Web of Science ®Google Scholar
• Kleinman ME, Baffi JZ, Ambati J. The multifactorial nature of retinal vascular disease. Ophthalmologica. 2010;224(Suppl 1):16–24. doi:10.1159/000315152
   PubMed Web of Science ®Google Scholar
• Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615–625. doi:10.1016/j.ophtha.2011.01.031
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 Phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801. doi:10.1016/j.ophtha.2011.12.039
   PubMed Web of Science ®Google Scholar
• Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013–2022. doi:10.1016/j.ophtha.2013.02.034
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–1203. doi:10.1056/NEJMoa1414264
   PubMed Web of Science ®Google Scholar
• Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology. 2016;123(11):2376–2385. doi:10.1016/j.ophtha.2016.07.032
   PubMed Web of Science ®Google Scholar
• Cai S, Bressler NM. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T. Curr Opin Ophthalmol. 2017;28(6):636–643. doi:10.1097/ICU.0000000000000424
   PubMed Web of Science ®Google Scholar
• Boyer DS, Yoon YH, Belfort R, et al. Three-year, randomized, sham controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904–1914. doi:10.1016/j.ophtha.2014.04.024
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. doi:10.1186/2046-4053-4-1
   PubMed Web of Science ®Google Scholar
• Abouhussein MA, Gomaa AR. Aflibercept plus micropulse laser versus aflibercept monotherapy for diabetic macular edema: 1-year results of a randomized clinical trial. Int Ophthalmol. 2020;40(5):1147–1154. doi:10.1007/s10792-019-01280-9
   Web of Science ®Google Scholar
• Baker CW, Glassman AR, Beaulieu WT, et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA. 2019;321(19):1880–1894. doi:10.1001/jama.2019.5790
   PubMed Web of Science ®Google Scholar
• Bhandari S, Nguyen V, Fraser-Bell S, et al. Ranibizumab or aflibercept for diabetic macular edema: comparison of 1-year outcomes from the fight retinal blindness! registry. Ophthalmology. 2019;127(5):608–615. doi:10.1016/j.ophtha.2019.11.018
   Web of Science ®Google Scholar
• Polo RC, Sànchez CR, Guisado DMG, Luque JMD. Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice. Clin Ophthalmol. 2018;12:99–104. doi:10.2147/OPTH.S154421
   Web of Science ®Google Scholar
• Chen YX, Li XX, Yoon YH, et al. Intravitreal aflibercept versus laser photocoagulation in asian patients with diabetic macular edema: the VIVID-east study. Clin Ophthalmol. 2020;14:741–750. doi:10.2147/OPTH.S235267
   Web of Science ®Google Scholar
• Ciulla TA, Bracha P, Pollack J, Williams DF. Real-world outcomes of anti–vascular endothelial growth factor therapy in diabetic macular edema in the United States. Ophthalmol Retina. 2018;2(12):1179–1187. doi:10.1016/j.oret.2018.06.004
   PubMedGoogle Scholar
• Curry BA, Sanfilippo PG, Chan S, Hewitt AW, Verma N. Clinical outcomes of a treat and extend regimen with intravitreal aflibercept injections in patients with diabetic macular edema: experience in clinical practice. Ophthalmol Ther. 2020;9(1):87–101. doi:10.1007/s40123-019-00224-x
   Web of Science ®Google Scholar
• Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the da VINCI study of VEGF trap-eye in eyes with diabetic macular edema. Ophthalmology. 2012;119(8):1658–1665. doi:10.1016/j.ophtha.2012.02.010
   PubMed Web of Science ®Google Scholar
• Fouda SM, Bahgat AM. Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema. Clin Ophthalmol. 2017;11:567–571. doi:10.2147/OPTH.S131381
   PubMed Web of Science ®Google Scholar
• Garweg JG, Stefanickova J, Hoyng C, et al. Vision-related quality of life in patients with diabetic macular edema treated with intravitreal aflibercept: the AQUA study. Ophthalmol Retina. 2019;3(7):567–575. doi:10.1016/j.oret.2019.03.012
   Google Scholar
• Glassman AR, Baker CW, Beaulieu WT, et al. Assessment of the DRCR retina network approach to management with initial observation for eyes with center-involved diabetic macular edema and good visual acuity: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2020;138(4):341–349. doi:10.1001/jamaophthalmol.2019.6035
   PubMed Web of Science ®Google Scholar
• Hernández-Bel L, Cervera-Taulet E, Navarro-Palop C, Castro-Navarro V, Chiarri-Toumit C, Montero-Hernández J. Sequential dexamethasone and aflibercept treatment in patients with diabetic macular edema: structural and functional outcomes at 52 weeks. Ophthalmologica. 2019;241(2):98–104. doi:10.1159/000489345
   Web of Science ®Google Scholar
• Kern C, Schiefelbein J, Fu JD, et al. Two year visual acuity and structural outcomes in patients with diabetic macular oedema treated with intravitreal aflibercept – a retrospective cohort study. Clin Ophthalmol. 2020;14:533–541. doi:10.2147/OPTH.S237586
   Web of Science ®Google Scholar
• Khattab AM, Hagras SM, AbdElhamid AH, Torky MA, Awad EA, Abdelhameed AG. Aflibercept with adjuvant micropulsed yellow laser versus aflibercept monotherapy in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2019;257(7):1373–1380. doi:10.1007/s00417-019-04355-6
   PubMed Web of Science ®Google Scholar
• Korobelnik JF, Daien V, Faure C, et al. Real-world outcomes following 12 months of intravitreal aflibercept monotherapy in patients with diabetic macular edema in France: results from the APOLLON study. Graefes Arch Clin Exp Ophthalmol. 2020;258(3):521–528. doi:10.1007/s00417-019-04592-9
   PubMed Web of Science ®Google Scholar
• Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247–2254. doi:10.1016/j.ophtha.2014.05.006
   PubMed Web of Science ®Google Scholar
• Ozkaya A, Demir G, Kirmaci A. Comparison of aflibercept and ranibizumab in diabetic macular edema associated with subretinal detachment. Eur J Ophthalmol. 2019;30(2):363–369. doi:10.1177/1120672119827855
   Web of Science ®Google Scholar
• Ozsaygili C, Duru N. Comparison of intravitreal dexamethasone implant and aflibercept in patients with treatment-naive diabetic macular edema with serous retinal detachment. Retina. 2019;40(6):1044–1052. doi:10.1097/IAE.0000000000002537
   Web of Science ®Google Scholar
• Pak KY, Shin JP, Kim HW, et al. One-year results of treatment of diabetic macular edema with aflibercept using the treat-and-extend dosing regimen: the VIBIM study. Ophthalmologica. 2020;243(4):255–262. doi:10.1159/000504753
   Web of Science ®Google Scholar
• Schwarzer P, Ebneter A, Munk M, Wolf S, Zinkernagel MS. One-year results of using a treat-and-extend regimen without a loading phase with anti-VEGF agents in patients with treatment-naive diabetic macular edema. Ophthalmologica. 2019;241(4):220–225. doi:10.1159/000495623
   Web of Science ®Google Scholar
• Bilgic A, Sudhalkar A, Kodjikian L, et al. Pro re nata dexamethasone implant for treatment-naive phakic eyes with diabetic macular edema: a prospective study. Ophthalmol Retina. 2019;3(11):929–937. doi:10.1016/j.oret.2019.05.027
   Google Scholar
• Borrelli E, Parravano M, Querques L, et al. One-year follow-up of ischemic index changes after intravitreal dexamethasone implant for diabetic macular edema: an ultra-widefield fluorescein angiography study. Acta Diabetol. 2019;57(5):543–548. doi:10.1007/s00592-019-01435-1
   Web of Science ®Google Scholar
• Callanan DG, Loewenstein A, Patel SS, et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2016;255(3):463–473. doi:10.1007/s00417-016-3472-1
   Web of Science ®Google Scholar
• Chhablani J, Bansal P, Veritti D, et al. Dexamethasone implant in diabetic macular edema in real-life situations. Eye (Lond). 2015;30(3):426–430. doi:10.1038/eye.2015.246
   Web of Science ®Google Scholar
• Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014;121(12):2473–2481. doi:10.1016/j.ophtha.2014.07.002
   PubMed Web of Science ®Google Scholar
• Iglicki M, Busch C, Zur D, et al. Dexamethasone implant for diabetic macular edema in naive compared with refractory eyes: the international retina group real-life 24-month multicenter study: the irgrel-dex study. Retina. 2018;39(1):44–51. doi:10.1097/IAE.0000000000002196
   Web of Science ®Google Scholar
• Maggio E, Sartore M, Attanasio M, et al. Anti–vascular endothelial growth factor treatment for diabetic macular edema in a real-world clinical setting. Am J Ophthalmol. 2018;195:209–222. doi:10.1016/j.ajo.2018.08.004
   PubMed Web of Science ®Google Scholar
• Malcles A, Dot C, Voirin N, et al. Real-life study in diabetic macular edema treated with dexamethasone implant: the reldex study. Retina. 2017;37(4):753–760. doi:10.1097/IAE.0000000000001234
   PubMed Web of Science ®Google Scholar
• Matonti F, Pommier S, Meyer F, et al. Long-term efficacy and safety of intravitreal dexamethasone implant for the treatment of diabetic macular edema. Eur J Ophthalmol. 2016;26(5):454–459. doi:10.5301/ejo.5000787
   PubMed Web of Science ®Google Scholar
• Menezo M, Roca M, Menezo V, Pascual I. Intravitreal dexamethasone implant ozurdex in the treatment of diabetic macular edema in patients not previously treated with any intravitreal drug: a prospective 12-month follow-up study. Curr Med Res Opin. 2019;35(12):2111–2116. doi:10.1080/03007995.2019.1652449
   PubMed Web of Science ®Google Scholar
• Ozkaya A, Algaroz C, Algaroz N, et al. Dexamethasone implant in pseudophakic and nonglaucomatous subgroup of diabetic macular edema patients: a real life experience. Eur J Ophthalmol. 2016;26(4):351–355. doi:10.5301/ejo.5000725
   Web of Science ®Google Scholar
• Pareja-Ríos A, Ruiz-de la Fuente-rodríguez P, Bonaque-González S, López-Gálvez M, Lozano-López V, Romero-Aroca P. Intravitreal dexamethasone implants for diabetic macular edema. Int J Ophthalmol. 2018;11(1):77–82. doi:10.18240/ijo.2018.01.14
   PubMed Web of Science ®Google Scholar
• Rajesh B, Zarranz-Ventura J, Fung TA, et al. Safety of 6000 intravitreal dexamethasone implants. Br J Ophthalmol. 2019;104(1):39–46. doi:10.1136/bjophthalmol-2019-313991
   Web of Science ®Google Scholar
• Jabbarpoor Bonyadi MH, Baghi A, Ramezani A, Yaseri M, Soheilian M. One-year results of a trial comparing 2 doses of intravitreal ziv-aflibercept versus bevacizumab for treatment of diabetic macular edema. Ophthalmol Retina. 2017;2(5):428–440. doi:10.1016/j.oret.2017.09.010
   Google Scholar
• Koç I, Kadayifcilar S, Eldem B. Real-world results of intravitreal ranibizumab, bevacizumab, or triamcinolone for diabetic macular edema. Ophthalmologica. 2018;239(2–3):85–93. doi:10.1159/000481180
   Web of Science ®Google Scholar
• Kriechbaum K, Prager S, Mylonas G, et al. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye. 2014;28(1):10–16. doi:10.1038/eye.2013.242
   Web of Science ®Google Scholar
• Matsuda S, Tam T, Singh RP, et al. The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema. J Diabetes Complications. 2014;28(2):166–170. doi:10.1016/j.jdiacomp.2013.11.009
   PubMed Web of Science ®Google Scholar
• Georgios M, Schranz M, Scholda C, et al. Response of retinal sensitivity to intravitreal anti-angiogenic bevacizumab and triamcinolone acetonide for patients with diabetic macular edema over one year. Curr Eye Res. 2020;45(9):1107–1113. doi:10.1080/02713683.2020.1712728
   Web of Science ®Google Scholar
• Nepomuceno AB, Takaki E, Paes de Almeida FP, et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. Am J Ophthalmol. 2013;156(3):502–513. doi:10.1016/j.ajo.2013.04.026
   PubMed Web of Science ®Google Scholar
• Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117(6):1078–1086. doi:10.1016/j.ophtha.2010.03.045
   PubMed Web of Science ®Google Scholar
• Sobaci G, Ozge G, Erdurman C, Durukan HA, Bayraktar ZM. Comparison of grid laser, intravitreal triamcinolone, and intravitreal bevacizumab in the treatment of diffuse diabetic macular edema. Ophthalmologica. 2011;227(2):95–99. doi:10.1159/000331322
   Web of Science ®Google Scholar
• Yaseri M, Zeraati H, Mohammad K, et al. Intravitreal bevacizumab injection alone or combined with triamcinolone versus macular photocoagulation in bilateral diabetic macular edema; application of bivariate generalized linear mixed model with asymmetric random effects in a subgroup of a clinical trial. J Ophthalmic Vis Res. 2014;9(4):453–460. doi:10.4103/2008-322X.150818
   Google Scholar
• Baget-Bernaldiz M, Romero-Aroca P, Bautista-Prez A, Mercado J. Multifocal electroretinography changes at the 1-year follow-up in a cohort of diabetic macular edema patients treated with ranibizumab. Doc Ophthalmol. 2017;135(2):85–96. doi:10.1007/s10633-017-9601-2
   Web of Science ®Google Scholar
• Berger A, Sheidow T, Cruess AF, Arbour JD, Courseau AS, de Takacsy F. Efficacy/safety of ranibizumab monotherapy or with laser versus laser monotherapy in DME. Can J Ophthalmol. 2015;50(3):209–216. doi:10.1016/j.jcjo.2014.12.014
   Web of Science ®Google Scholar
• Brown DM, Ou WC, Wong TP, Kim RY, Croft DE, Wykoff CC, for DAVE study group. Targeted retinal photocoagulation for diabetic macular edema with peripheral retinal nonperfusion: three-year randomized DAVE trial. Ophthalmology. 2018;125(5):683–690. doi:10.1016/j.ophtha.2017.11.026
   PubMed Web of Science ®Google Scholar
• Chatziralli I, Santarelli M, Patrao N, et al. Identification of time point to best define sub-optimal response’ following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data. Eye (Lond). 2017;31(11):1594–1599. doi:10.1038/eye.2017.111
   PubMed Web of Science ®Google Scholar
• Chen YP, Wu AL, Chuang CC, Chen SN. Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab: comparison between responder and non-responder cases. Sci Rep. 2019;9(1):10952. doi:10.1038/s41598-019-47241-1
   PubMed Web of Science ®Google Scholar
• Epstein D, Amrèn U. Long-time outcome in patients treated with ranibizumab for diabetic macular edema: a 4-year study. Retina. 2018;38(1):183–186. doi:10.1097/IAE.0000000000001501
   Web of Science ®Google Scholar
• Ghanchi F, Hazel CA. South Asian diabetic macular oedema treated with ranibizumab (ADMOR)-real-life experience. Eye (Lond). 2016;30(1):133–138. doi:10.1038/eye.2015.209
   PubMed Web of Science ®Google Scholar
• Hrarat L, Fajnkuchen F, Boubaya M, et al. Outcomes after a 1-year treatment with ranibizumab for diabetic macular edema in a clinical setting. Ophthalmologica. 2016;236(4):207–214. doi:10.1159/000453006
   Web of Science ®Google Scholar
• Ishibashi T, Li X, Koh A, et al. The REVEAL study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology. 2015;122(7):1402–1415. doi:10.1016/j.ophtha.2015.02.006
   PubMed Web of Science ®Google Scholar
• James DGP, Mitkute D, Porter G, Vayalambrone D. Visual outcomes following intravitreal ranibizumab for diabetic macular edema in a pro re nata protocol from baseline: a real-world experience. Asia Pac J Ophthalmology (Phila). 2019;8(3):200–205.
   Web of Science ®Google Scholar
• Karst SG, Lammer J, Mitsch C, Schmidt-Erfurth U. Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment — reply to the letter to the editor. Graefes Arch Clin Exp Ophthalmol. 2017;256(5):1039–1040. doi:10.1007/s00417-018-3902-3
   Web of Science ®Google Scholar
• Tso-Ting L, Chung-May Y, Chang Hao Y, Ho TC, Hsieh YT. Treatment outcomes and predicting factors for diabetic macular edema treated with ranibizumab – one-year real-life results in Taiwan. J Formos Med Assoc. 2019;118(1 Pt 1):194–202. doi:10.1016/j.jfma.2018.03.009
   Web of Science ®Google Scholar
• Li X, Dai H, Li X, et al. Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study. Graefes Arch Clin Exp Ophthalmol. 2019;257(3):529–541. doi:10.1007/s00417-018-04213-x
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Khwaia AA, et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2010;117(11):2146–2151. doi:10.1016/j.ophtha.2010.08.016
   PubMed Web of Science ®Google Scholar
• Ozkaya A, Ozveren M, Demircan A. The real life data of ranibizumab use among the diabetic macular edema patients in Turkey: documenting the improvement with clinical optimization during three consecutive years. Saudi J Ophthalmol. 2018;32(3):175–179. doi:10.1016/j.sjopt.2018.04.005
   PubMed Web of Science ®Google Scholar
• Patrao NV, Antao S, Egan C, et al. Real-world outcomes of ranibizumab treatment for diabetic macular edema in a United Kingdom National Health Service setting. Am J Ophthalmol. 2016;172:51–57. doi:10.1016/j.ajo.2016.09.002
   PubMed Web of Science ®Google Scholar
• Payne JF, Wykoff CC, Lloyd Clark W, Bruce BB, Boyer DS, Brown DM, for TREX-DME study Group. Randomized trial of treat and extend ranibizumab with and without navigated laser for diabetic macular edema: TREX-DME 1 year outcomes. Ophthalmology. 2017;124(1):74–81. doi:10.1016/j.ophtha.2016.09.021
   PubMed Web of Science ®Google Scholar
• Prager SG, Lammer J, Mitsch C, et al. Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone. Acta Ophthalmol. 2018;96(2):e195–e200. doi:10.1111/aos.13520
   Web of Science ®Google Scholar
• Prünte C, Fajnkuchen F, Mahmood S, et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol. 2016;100(6):787–795. doi:10.1136/bjophthalmol-2015-307249
   PubMed Web of Science ®Google Scholar
• Sato S, Shinoda H, Nagai N, et al. Predictive factors of better outcomes by monotherapy of an antivascular endothelial growth factor drug, ranibizumab, for diabetic macular edema in clinical practice. Medicine (Baltimore). 2017;96(16):e6459. doi:10.1097/MD.0000000000006459
   PubMed Web of Science ®Google Scholar
• Takasago Y, Fujita T, Nakano Y, et al. Ranibizumab treatment improves diabetic macular oedema without influencing retinal oximetry parameters. Acta Ophthalmol. 2019;97(8):e1048–e1053. doi:10.1111/aos.14145
   Web of Science ®Google Scholar
• Talks SJ, Bhatia D, Menon G, et al. Randomised trial of wide-field guided PRP for diabetic macular oedema treated with ranibizumab. Eye (Lond). 2019;33(6):930–937. doi:10.1038/s41433-019-0342-1
   PubMed Web of Science ®Google Scholar
• Tsai MJ, Hsieh YT, Peng YJ. Real-life experience of ranibizumab for diabetic macular edema in Taiwan. Int Ophthalmol. 2019;39(7):1511–1522. doi:10.1007/s10792-018-0970-7
   PubMed Web of Science ®Google Scholar
• Xu Y, Rong A, Xu W, Niu Y, Wang Z. Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study. BMC Ophthalmol. 2017;17(1):158. doi:10.1186/s12886-017-0554-8
   Web of Science ®Google Scholar
• Ciulla TA, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28,658 patient eyes. Br J Ophthalmol. 2020;bjophthalmol-2020-315933. doi:10.1136/bjophthalmol-2020-315933
   Web of Science ®Google Scholar
• Blinder KJ, Dugel PU, Chen S, et al. Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (echo study report 1). Clin Ophthalmol. 2017;11:393–401. doi:10.2147/OPTH.S128509
   PubMed Web of Science ®Google Scholar
• Holekamp NM, Campbell J, Almony A, et al. Vision outcomes following anti-vascular endothelial growth factor treatment of diabetic macular edema in clinical practice. Am J Ophthalmol. 2018;191:83–91. doi:10.1016/j.ajo.2018.04.010
   PubMed Web of Science ®Google Scholar
• Tufanaru C, Munn Z, Stephenson M, Aromataris E. Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness. Int J Evid Based Healthc. 2015;13(3):196–207. doi:10.1097/XEB.0000000000000065
   PubMed Web of Science ®Google Scholar
• Kodjikian L, Bellocq D, Mathis T. Pharmacological management of diabetic macular edema in real-life observational studies. Biomed Res Int. 2018;2018:8289253. doi:10.1155/2018/8289253
   PubMed Web of Science ®Google Scholar
• Rosenblatt A, Udaondo P, Cunha-Vaz J, et al. A collaborative retrospective study on the efficacy and safety of intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema. Ophthalmology. 2020;127(3):377–393. doi:10.1016/j.ophtha.2019.10.005
   PubMed Web of Science ®Google Scholar
• Veritti D, Sarao V, Galiazzo F, Lanzetta P. Early effects of dexamethasone implant on macular morphology and visual function in patients with diabetic macular edema. Ophthalmologica. 2017;238(1–2):100–105. doi:10.1159/000475889
   Web of Science ®Google Scholar
• Sarao V, Veritti D, Furino C, et al. Dexamethasone implant with fixed or individualized regimen in the treatment of diabetic macular oedema: six-month outcomes of the UDBASA study. Acta Ophthalmol. 2017;95(4):e255–e260. doi:10.1111/aos.13395
   Web of Science ®Google Scholar
• Al-Khersan H, Hariprasad SM, Chhablani J; for Dex Implant Study Group. Early response to intravitreal dexamethasone implant therapy in diabetic macular edema may predict visual outcome. Am J Ophthalmol. 2017;184:121–128. doi:10.1016/j.ajo.2017.10.004
   PubMed Web of Science ®Google Scholar
• Wecker T, Ehlken C, Bühler A, et al. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Br J Ophthalmol. 2017;101(3):353–359. doi:10.1136/bjophthalmol-2016-308668
   PubMed Web of Science ®Google Scholar
• Lanzetta P, Loewenstein A, for Vision Academy Steering C. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017;255(7):1259–1273. doi:10.1007/s00417-017-3647-4
   PubMed Web of Science ®Google Scholar
• Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology. 2015;122(10):2044–2052. doi:10.1016/j.ophtha.2015.06.017
   PubMed Web of Science ®Google Scholar
• Heier JS, Bressler NM, Avery RL, et al. Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema: extrapolation of data to clinical practice. JAMA Ophthalmol. 2016;134(1):95–99. doi:10.1001/jamaophthalmol.2015.4110
   PubMed Web of Science ®Google Scholar
• Dugel PU, Hillenkamp J, Sivaprasad S, et al. Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials. Clin Opthalmol. 2016;10:1103–1110. doi:10.2147/OPTH.S100764
   Google Scholar